GlaxoSmithKline Holdings (Americas) Inc. - Page 11




                                       - 11 -                                         
          was unable to bring action immediately and claim concerned events           
          and transactions which had taken place many years earlier).                 
               In sum, the application shows that there is a reasonable               
          expectation that the applicants will be adversaries in an action            
          cognizable in the Court and there is a significant risk that                
          critical testimony may be lost over the next several years                  
          because of Messrs. Girolami’s and Jack’s advanced ages.                     
          Consistent with the preceding discussion, and with the intention            
          of preventing a failure of justice in this matter, we will grant            
          the applicants’ Joint Application to Perpetuate Testimony Before            
          Commencement of a Case, with appropriate terms and conditions to            
          be set forth in our order.  Insofar as the applicants request               
          that we include a discovery schedule in our order, we deny the              
          request.                                                                    
               To reflect the foregoing,                                              
                                             An order will be issued                  
                                        granting the applicants’ Joint                
                                        Application to Perpetuate                     
                                        Testimony Before Commencement                 
                                        of a Case.                                    













Page:  Previous  1  2  3  4  5  6  7  8  9  10  11  

Last modified: May 25, 2011